Interpretation of results from genome-wide association studies for T2D is challenging. Only very few loci have been replicated in African ancestry populations and the identification of the implicated functional genes remain largely undefined.
INTRODUCTION
No disease with a genetic predisposition has been more intensely investigated than Type 2 diabetes (T2D [MIM: 125853]), the world's most widespread and devastating metabolic disorder. Over the last 10 years, numerous consortia have undertaken to characterize the genetic causes of T2D through a very large number (>30) of genome-wide association studies (GWAS), and large-scale meta-analyses. Initially based on Europeans, the focus has now shifted to the replication of risk loci in additional ethnicities (trans-ethnic studies), motivated in part by the likely wider application of cosmopolitan variants for translational research, but also the desire for increasingly larger research sample sizes in order to try to boost study power 1 . But since T2D is really a group of diseases 2 , increased sample size should be met with scepticism unless accompanied by more detailed clinical phenotypes and strategies to minimise disease heterogeneity. Recent trans-ethnic meta-analysis of T2D for four populations (Europeans, East Asians, South Asians and Mexican Americans) has identified seven T2D loci 3 , in addition to the previously published list of 69 loci 4 . However, a large proportion of these 76 loci 3 do not show evidence for nominal association for the same 'lead' SNP. Since the lead SNP is unlikely to be the causal variant, this low replication rate is a general problem for trans-ethnic studies 5 . The inability to account for genetic distance between neighbouring SNPs and genetic heterogeneity (e.g. locus and allele heterogeneity and variation in LD between populations) are both potential thwarting factors in the endeavour to identify trans-ethnic disease loci.
On the other hand, the prevalence of T2D in African-Americans (19%) at approximately twice that of European Americans (10%), and the existence of more genetic diversity in peoples of African ancestry, partly due to less extensive linkage disequilibrium (LD), also gives rise to a major opportunity for comparative fine mapping studies 3; 6; 7 . This possibility was missed by a recent major trans-ethnic meta-analysis that unfortunately excluded African-Americans 3 . Here we seek to take advantage of this ancestry group by using a mapping approach to identify cosmopolitan T2D locations, which avoids the focus on lead SNPs. Instead we use high-resolution genetic maps to identify new cosmopolitan T2D susceptibility loci that are shared by both European and African-American populations.
Genetic distances from these maps accurately capture the genetic architecture of the relevant population and have been successfully used in gene mapping studies for other common diseases 8; 9 . We constructed genetic maps for each of these two populations and then used disease-associated location estimates on these maps as the basis for the precise co-localization and replication in both populations. We also analysed all 76 previously known T2D loci 3 to obtain refined location estimates on the same genetic maps. Since an estimated 90% of variants with a functional role in complex traits such as T2D are likely to be non-coding and regulatory 10 , we assessed this scenario by exploiting publicly available subcutaneous adipose expression data. The hypothesis we tested is that T2D disease loci confer risk of disease by acting as expression quantitative trail loci (eQTL) that regulate the expression of neighbouring (cis-) genes. To test this hypothesis, we used the same genetic maps to assess whether the location estimates for eQTL also precisely collocated with those mapped for T2D in this whole-genome analysis, thereby identifying potential cis-genes and pathways regulated by the disease loci. Finally, we performed fine 5 mapping using targeted next generation sequencing (NGS) of the refined location estimates for one previously known locus (TCFL72) and two of the additional cosmopolitan loci from this study using independent case/control sample data, with the aim of identifying the candidate functional variants at the causal location estimates. These examples illustrate a way forward for the systematic identification of putative functional variants at these identified disease-associated eQTLs, coupled with the integration of functional annotation such as cell-specific chromatin domain modifications, enhancers and transcription binding sites.
METHODS

STUDY DESIGN
We analysed two European (EUR) and one African-American (AA) samples with a total of 5,800 T2D cases and 9,691 controls. The two independent EUR samples (SNP-arrays for GWA and Metabochip) were obtained from the Wellcome Trust Case Control Consortium (WTCCC) 11; 12 with a description of diagnostic criteria and sample matching provided in Supplementary Materials. The AA GWA sample for a population of predominantly African ancestry was obtained from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 13 . Analysing "one-SNP-at-a-time" ignores LD structure when testing for association with disease or gene expression. Here we use population-specific genetic maps, which provide (i) commensurability when making comparisons between different populations and SNP arrays; (ii) the means to implement a multi-marker test of association 14 ; (iii) genetic distances between loci when testing for association with disease or adipose expression; and (iv) precise location estimates on the genetic map for potential functional variants, since these estimates are more efficient than using physical maps 15 . We constructed two high-resolution genetic maps based upon HapMap data with genetic distances expressed in LD units (LDU) 16 . The EUR LDU map was used for analyses of the two EUR T2D datasets and the AA LDU map was used for the analysis of the AA T2D dataset. The autosomal genome (sex chromosomes were not included in the analyses) was divided into 4,800 non-overlapping analytical windows with a minimum LDU distance of 10 LDU. In addition to windows being the same minimum size on the genetic map, each window also had to include a minimum of 30 SNPs. These criteria yielded an average genetic length of 11 LDU. The identical boundaries in kilobases (kb) for all 4,800 analytical windows were used for the AA dataset, but with longer average genetic length (16 LDU) , reflecting a population history of greater antiquity with additional historical recombination events. All SNPs in each analytical window were simultaneously used to test for association with disease using a multi-marker LDU model 14 . The analysis returns one estimated location for a causal variant with the strongest signal, along with the association test P-value for each window. Utilizing the genetic map in this way, the multimarker test of association models the degree of regional LD when estimating the location of a putative causal variant on the genetic map. A schematic diagram of the functional genomic strategy used in the current study is provided in Figure 1 . Strict criteria were used for the meta-analysis. Location estimates for genome-wide significant meta-analysis loci had to be nominally significant in both ancestry groups for the cosmopolitan loci and in both European samples for the European-specific loci. An interval criterion was used where location estimates from different datasets had to be within <100 kb of one another to qualify as a potential replication. Replicated loci had to pass a Bonferroni corrected meta-analysis P-value threshold of 1x10 -5 , based on the total number of genomic tests performed (=0.05/4,800). We refer to the co-location interval (distance between location estimates)
as the genomic region that most plausibly include the functional variants that confer risk of T2D.
We conducted in silico functional gene expression analyses to assess whether the same T2D loci are also eQTL that regulate the expression of neighbouring cis-genes using data generated by the MuTHER consortium 17 . Summary statistics for the probes and SNPs are available from the MuTHER website. Using adipose tissue mRNA expression probes as quantitative traits; we tested for cis-association at each disease locus by employing the same multi-locus LDU model, with potential regulated cis-genes defined to be within 1.5
Mb distance either side of each replicated T2D causal locations ( Figure 1 ). We only considered a disease locus to be a potential eQTL, if the estimated eQTL co-located to within 50 kb of the T2D location and passed Bonferroni correction for the total number of probes tested within 1.5 Mb of each replicated disease locus. All LDU location estimates for both T2D and eQTL on the genetic map were converted back to kb B36 (NCBI36/hg18) for presentational purposes.
Finally, we conducted a NGS targeted re-sequencing experiment for three of the disease loci. Next generation sequencing was conducted using the Agilent SureSelect XT2 capture kit following manufacturer protocol guidelines for 100 ng of DNA. Blood DNA samples were sequenced for a total of 94 unrelated European individuals with T2D and 94 unaffected controls 1:1 matched for age, BMI and sex. Cases with a family history of T2D
(selection and diagnosis criteria described elsewhere) 18 and controls were selected from families originally collected for an obesity (MIM: 601665) study without a history of T2D 19 . Additional method details are provided in the supplementary material. Tables 1 and 2 For the 111 additional T2D loci, half of the location estimates are intragenic and half are intergenic. For the latter, we follow the convention of labeling the disease loci using the nearest gene symbol (within 100kb from the T2D location). The in silico expression analyses, however, indicate which cis-genes are regulated and therefore functionally implicated by the identified T2D loci. Two-thirds (71/111) of the disease loci also show strong evidence of being eQTLs using our stringent criteria but the remaining one-third may well reflect that these replicated loci could be eQTLs for a T2D-relevant tissue other than subcutaneous adipose. The 71 eQTL signals regulate the expression of a conservatively estimated total of 183 cis-genes (Tables 1 and 2 Figure S1 ). This result demonstrates that the assumption that the nearest gene is also the most likely candidate functional gene is not justified. Further analysis of the 183 cis-genes also showed that the distance between the eQTL and the T2D location estimates is not biased by the distance between the T2D sample location estimates within the <100kb interval (see supplementary Figure S2 ).
RESULTS
ADDITIONAL LOCI FOR T2D
Interestingly, approximately 40% of the eQTL signals observed in this study have at least one cis-gene previously known as one whose expression (in adipose or liver) is also strongly associated with BMI in morbidly obese individuals 20 . We also show that a number of the identified T2D loci also regulate the expression levels of nuclear encoded mitochondrial genes. For example, many cis-genes implicate T2D through the regulation of the molecular functions of fatty acid metabolism (PCCA To further characterize the observed T2D and associated eQTL location estimates in relation to potential functional variants, three of the cosmopolitan loci were targeted for sequencing using an independent sample of Europeans. 21 has previously been shown to overlap with T2D loci 22 , but such marks are often cell type-specific 23 . Figure 2c plots the -log10 P-values of the chromatin profiles, demonstrating that T2D causal locations also co-localize with chromatin domains for CD14+ monocytes and adipose nuclei. The most intense chromatin peaks were observed in CD14+ monocytes at the precise eQTL location for KLF4 and at rs60388922 and rs72756001 SNPs, which reside within the E and A T2D interval. Hence both of these SNPs are good causal candidate variants. respectively. This is a gene-rich region (57 genes in total), but for clarity only the six identified cis-genes have been plotted. East and South Asians and Mexican Americans). Using information from the human pancreatic islet regulome 22 , where sequences targeted by islet transcription factors highlight active enhancers, we observed that the identified T2D location resides within a cluster of such active enhancers. The transcription factor FOXA2-bound sites are also plotted within the kb boundaries of the active enhancer cluster. Chromatin peaks also overlap with the regulatory T2D and eQTL locations for pancreas and liver cell types (Fig.   3c ), suggesting evidence for more than one functional mutation within this region. The full interval for the T2D and eQTL locations were not entirely covered by NGS data, but nevertheless, the associated NGS SNPs reside between two active islet enhancers (Fig. 3b) .
In contrast to imputation methods that use high-resolution "out-of-sample" marker panels to infer missing SNPs to subsequently test one at a time, LDU analysis uses marker panels to infer high-resolution genetic maps. Subsequently, multi-marker tests of association use genetic distances for SNP arrays placed on those maps to infer the location of diseaseassociated functional variants. Fine mapping is therefore achieved by inferring fine-scale genetic maps, not by imputing SNPs. It is worth noting in relation to this that using the KCNK3 locus as an example, the NGS SNPs genotyped for the case control data that were associated with T2D status (Fig. 3a) could not be imputed based on the 1000G data as the reference panel.
FINDINGS AT PREVIOUSLY KNOWN T2D LOCI
Using the same data and analytical methods, we have confirmed disease location estimates for 62 out of 76 previously known loci 3 (supplementary Table S1 ). Of these, about half (33/62) show evidence of being eQTL with the majority regulating cis-genes over 1Mb
away. In addition, over one third (22/62) of the loci replicate for AA samples, which were previously excluded from trans-ethnic meta-analysis 3 . We investigated the Transcription factor 7-like 2 (TCF7L2 [MIM: 602228]) locus (signal 117, supplementary Table S1 ). Figure 4b plots the T2D locations for EUR and AA and shows that this signal harbours a cis-eQTL for the distant GPAM. The T2D re-sequence variants we identified, which colocate to the <30 kb interval between the T2D and eQTL locations, account for a large risk of disease (OR=1.7-2.6). The summary statistics in Figure 4a show that these risk variants are the major allele in all other human populations. The T2D locations for both populations reside within an active enhancer cluster that is targeted by transcription factor FOXA2 (kb locations of the regulatory elements are plotted on the X-axis). Inferring the likely transcriptional activity by observing the chromatin state, we show that the eQTL, T2D colocations and NGS SNPs all map precisely to highly significant H3K4me3 and H3K27ac peaks, in particular in adipose cells (Fig. 4c) . This illustrates the importance of co-locating within an interval on the genetic map, since it allows for potential allelic heterogeneity.
DISCUSSION
This study provides a comprehensive genomic catalogue of susceptibility loci for T2D in European and African ancestry populations and evidence that the majority of the additional 111 and 62 previously known disease loci are eQTLs for 183 and 83 cis-genes,
respectively. This implies that these disease loci confer risk of T2D, via the cis-regulation of the expression levels in tissue relevant to T2D for a large number (266 in total) of neighbouring genes. This study identifies a large number of disease loci at regulatory hotspots and replicates them in both European and African-American populations, with 84% (93/111) of the additional loci being cosmopolitan. This replication was made possible by analyses that make use of, rather than being confounded by, the fine-scale differences in LD between these two populations, where causal locations and also eQTLs are estimated on an LDU map, avoiding the ambivalence of interpreting individual GWAS SNPs.
Interestingly, recent results in the literature support our conclusion that cosmopolitan loci are more widespread than previously thought. For example, it was not until recently that the most established bona-fide TCF7L2 locus for T2D in Europeans was also confirmed in African ancestry groups in an extensive study that included 17 African-American GWA samples 7 . This is a locus that was identified in the present study, which included only one African-American sample.
The T2D associated common genetic variation in TCF7L2 is well established, but the mechanism by which risk of disease is conferred remains elusive. Our refined localization of this locus reveals that this is a regulatory site for the distant nuclear-encoded mitochondrial gene, GPAM, and identifies additional candidate causal variants GPAM is interesting as it is a key rate-limiting enzyme in lipogenesis and highly expressed in liver and adipose tissue. Nuclear-encoded mitochondrial genes are of particular interest in relation to T2D, since mitochondrial function has been demonstrated to impact upon a myriad of molecular and cellular functional processes implicated in T2D [24] [25] [26] . However, to date human genetic association studies have identified few, if any, nuclear-encoded mitochondrial genes that directly confer risk of T2D in its common form. In this study we have identified at least 11 further nuclear-encoded mitochondria genes, which are regulated by eQTLs that also appear to confer risk of T2D. This indicates that one of the molecular mechanisms that contribute to inherited risk of T2D is mitochondrial dysfunction in relation to energy metabolism. These findings are also supported by an independent study design that utilises transcriptome and proteome data to reconstruct metabolic pathways in myocytes and identify the same mitochondrial pathways implicated in our study for adipose tissue (namely, fatty acid beta-oxidation, Krebs cycle, pyruvate metabolism and branchedchain amino acid (valine, leucine, and isoleucine) metabolism) 27 .
Recent large scale whole genome and exome association studies 28 have empirically questioned any major role for coding variants in the aetiology of T2D and therefore make regulatory loci such as the ones highlighted in this study, all the more important to investigate. We believe that the targeted re-sequencing of informative refined regions using case/control data has the power to dissect the genetic epidemiology of T2D. While imputation methods can successfully infer missing genotypes for most genomic regions using population data as the reference data, ironically it appears that imputation methods are likely to fail to impute or to make correct inferences where it matters most (e.g. at disease loci with allelic spectra that differ from the general population). This important point requires further investigation.
Chromatin analyses and targeted re-sequencing of these refined regions can be used to identify potential causal variant locations. The two identified signals (ACTL7B and KCNK3), which we have investigated lends support to this approach. A cosmopolitan disease location interval that includes KCNK3 was observed to be a hotspot for the regulation of six neighboring genes, with OTOF of particular interest because of its known association with hearing loss (autosomal recessive forms of deafness 29 ). According to the NIDDK, the prevalence of low-or mid-frequency hearing impairment among diabetics is three times that of non-diabetics (28% compared with 9%) 30 with the potential mechanism operating via microvascular and neural damage due to long-term hyperglycaemia 31 .
Interestingly, adipose gene expression for OTOF has also been previously shown to be associated with BMI in the morbidly obese 29 providing further evidence of a functional role through a regulatory mechanism. Targeted re-sequencing within the KCNK3 location interval identified candidate causal variants with large effect sizes. As with the TCF7L2 locus, the T2D and eQTL locations were found to reside in pancreatic islet enhancer and FOXA2 transcription factor-binding sites. Studies have shown that dysregulation of islet enhancers is relevant to the underlying mechanisms of T2D 22 and a recent examination of some of the previously found T2D loci have been found to overlap with FOXA2-bound sites 32 .
The cosmopolitan T2D location interval near ACTL7B overlapped with chromatin peaks for CD14+ monocytes and included an eQTL for KLF4 and EPB41L4B. KLF4 is highly expressed in CD14+ monocytes and belongs to the Krüppel-like factor (KLF) family that consists of transcription factors that can activate or repress different genes involved in processes such as differentiation, development and cell cycle progression, with several of these proteins implicated in glucose homeostasis 33 . KLF4 is also used experimentally to induce pluripotent cells that can differentiate into insulin-producing cells 34 . EPB41L4B
codes for an erythrocyte membrane protein (EMP) with greatly increased EMP glycosylation observed in T2D subjects 35 with likely clinical implications 36 . It is recognized clinically that both obesity and T2D are associated with a state of abnormal inflammatory response. Here we show that the T2D variants and eQTL locations for KLF4
and EPB41L4B reside in regions with chromatin modifications mainly observed in CD14+
monocytes. Monocytes play a pivotal role in innate immunity and are involved in metabolic regulation 37 . It has been shown that unbalanced proinflammatory/anti-inflammatory markers of CD14+ cells is associated with metabolic disorder in obese T2D individuals 38 .
KLF4 is a critical regulator of monocyte differentiation 39 and EPB41L4B expression in subcutaneous and omental adipose is strongly associated with BMI in morbidly obese individuals 20 . Therefore, these T2D intragenic variants and the regulated cis-genes (KLF4 and EPB41L4B) are likely to be involved in an inflammatory pathway for obesity and T2D.
The complex causal chain between a gene and its effect on susceptibility cannot be unravelled until we have a full understanding of the regulatory genetic architecture that underpins T2D, and until the causal changes have been localized in the DNA sequence 40 .
Our results show that disease-associated loci in different populations, gene expression and cell-specific regulatory annotation can be effectively integrated by localizing these effects on high-resolution linkage disequilibrium maps. By exploiting these maps to refine causal location estimates, we have identified a genomic catalogue of cosmopolitan and European disease loci with correspondingly important clinical implications that provides important molecular insights and opportunities to understand the molecular basis of this devastating common disease.
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The two LDU genetic maps (Y-axis in LDU) for AA and EUR are plotted against the physical genomic region (X-axis in kb). Vertical solid line arrows represent the functional location estimates A and E that are associated with T2D in AA and EUR samples, respectively. The dotted line arrows are the locations of eQTLs.
C: -log10 P-values of cell type-specific chromatin profiles are plotted against the kb map. T2D, eQTL and NGS SNP locations overlap with the co-ordinates of the chromatin peaks. 
C: -log10 P-values of cell type-specific chromatin profiles are plotted against the kb map. T2D and eQTL locations overlap with the co-ordinates of the chromatin peaks. 
The two LDU genetic maps (Y-axis in LDU) for AA and EUR are plotted against the physical genomic region (X-axis in kb). Vertical solid line arrows represent the functional location estimates A and E that are associated with T2D in AA and EUR samples, respectively. The dotted line arrow is the location of eQTL.
C: -log10 P-values of cell type-specific chromatin profiles are plotted against the kb map. T2D, eQTL and NGS SNP locations overlap with the co-ordinates of the chromatin peaks.
